A new embryo testing alternative has recently been launched. Avrio Genetics’ new method employs non-invasive strategies to deliver accurate screening results and healthier embryos.
New York, United States - October 29, 2020 /PressCable/ —
Texas based fertility company Avrio Genetics has launched a non-invasive embryo testing method that is now globally available. This new method seeks to allow patients that require in vitro fertilization a safer alternative to the existing invasive measures. It also aims to introduce a more affordable way to test embryos for the fertility industry.
For more information visit http://www.AvrioGenetics.com.
The newly launched testing method comes as a result of Avrio Genetics’ commitment to providing life-changing reproductive and personalized healthcare services under one roof. They aim to use these non-invasive PGT-A, PGT-M, and ERT services to advance the fertility industry.
The previous method of testing embryos involved taking a biopsy and then performing genetic sequencing. This method helps professionals determine the genetic health of the embryo and allows the one with the highest chance of a successful pregnancy to be selected.
This method has been seen as invasive, dangerous, and has the potential of lowering the viability of the embryo. Additionally, it is expensive.
The new method proposed by Avrio Genetics aims to provide non-invasive and cost-effective embryo screening without disturbing the embryo and thus lowers the risk of it losing its viability.
This non-invasive method of testing embryos is not only safer, but it also aims to improve clinical outcomes. Concerning implantation rate, clinical pregnancy, ongoing pregnancy, and live birth, this method seeks to allow all clinical progressional goals to be achieved. It aims to save time at the clinical level and also to provide a second chance for embryos that were not initially ideal.
Additionally, the method aims to allow labs to have the results released in 24 hours, and seeks to avoid losses and failures that could occur during testing, and also aims to improve the performance of the test using artificial intelligence analytics.
Avrio Genetics aims to launch additional non-invasive embryo testing within the next six months.
Avrio Genetics CEO Brandon Hesinger gave the company a name of Greek origin that translates to the word tomorrow in English. He did this because he believes in a better tomorrow, and since the company’s inception in 2017, Brandon has partnered with several partner companies to achieve this ideal.
Interested parties can click on the link above for more information.
Contact Info:
Name: Brandon Hensinger
Email: Send Email
Organization: Avrio Genetics LLC
Address: 244 5th Ave Suite 1278, New York, NY 10001, United States
Phone: +1-919-345-1087
Website: http://www.AvrioGenetics.com
Source: PressCable
Release ID: 88983392
